Company Profile

Shire specializes in developing, producing, and marketing pharmaceutical products for the treatment of nervous system dysfunctions (hyperactivity, epilepsy, Alzheimer's disease, etc.), cancer, gastro-intestinal illnesses, and infectious diseases. Net sales break down by source of income as follows: - sales of products (95.3%); - other (4.7%): primarily franchise royalties. Net sales break down geographically as follows: the United States (63.6%), Ireland (0.4%) and other (36%).

Employees

Sector

Pharmaceuticals

More about the company

21/12/18	S&P 500 : Dealmakers brace for slowdown after third-strongest M&A year	RE
21/12/18	Asia M&A clocks second best on record, strength to persist despite trade troubles	RE
20/12/18	British shares falter as Fed, oil play Scrooge	RE
19/12/18	FTSE : GSK pulls FTSE 100 out of three-day rut, focus on Fed	RE
18/12/18	FTSE : Oil slide and growth worries smother FTSE 100 while mid-caps bounce	RE
17/12/18	FTSE : down sharply as ASOS profit alert sparks wider retail selloff	RE
07/12/18	FTSE : Oil helps FTSE 100 end turbulent week firmer, but Brexit weighs	RE
05/12/18	FTSE : falls as growth angst spreads	RE
05/12/18	Growth and trade nerves grind European shares down to two-week low	RE
05/12/18	Takeda Pharmaceutical : clears key hurdle as investors back $59 billion Shire deal	RE
05/12/18	Takeda Pharmaceutical : investors back $59 billion Shire deal, but wary of debt load	RE
21/11/18	Takeda Pharmaceutical : EU approves Takeda buying Shire, on divestment condition	RE
21/11/18	Takeda Pharmaceutical : Investor advisory firms back Takeda's $62 billion deal for Shire	RE

13/05/20	Takeda Pharmaceutical : Drugmaker Takeda expects 35% rise in net profit on lower buyout costs	AQ
04/02/20	Takeda Pharmaceutical : lifts FY 2019 earnings projections after Shire buyout	AQ
07/01/19	Shire : Form 8.3 - Takeda Pharmaceutical	PU
07/01/19	Shire : Form 8.3 -	PU
07/01/19	Shire : Form 8.5 (EPT/RI) - Replacement of Shire	PU

08/01/19	EN DIRECT DES MARCHES : Nissan, Dassault Aviation, STMicroelectronics, Sika, Samsung, Tessi...
07/01/19	Les affaires reprennent dans la pharmacie
21/12/18	Walt Disney : Le marché du M&A se prépare à une année 2019 moins faste
18/12/18	Shire : plombé par le déclassement de Takeda
05/12/18	Altran Technologies : Les craintes sur les taux et le commerce font plier les actions en Europe

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SHIRE	+2.42%	-.--%	-	-	0
ELI LILLY AND COMPANY	+2.16%	+3.11%	+43.49%	+160.56%	1,013B
JOHNSON & JOHNSON	-0.07%	+4.45%	+53.50%	+49.05%	574B
ABBVIE INC.	-0.08%	-0.08%	+17.37%	+63.19%	397B
ROCHE HOLDING AG	-0.37%	+4.97%	+21.24%	+15.95%	324B
ASTRAZENECA PLC	+0.85%	+2.79%	+24.89%	+15.93%	280B
NOVARTIS AG	+2.10%	+7.06%	+24.57%	+34.79%	273B
AMGEN INC.	+4.84%	+2.45%	+21.33%	+62.89%	182B
NOVO NORDISK A/S	-0.19%	+3.96%	-45.64%	-48.23%	194B
GILEAD SCIENCES, INC.	+3.61%	-2.56%	+15.16%	+61.66%	151B
Average	+1.68%	+2.65%	+19.55%	+46.20%	376.52B
Weighted average by Cap.	+1.40%	+3.99%	+29.38%	+72.74%

Shire Stock

Stocks

JE00B2QKY057

Pharmaceuticals

Latest news : Shire

Analysts' recommendations: Shire

Press Releases: Shire

News in other languages: Shire

Quotes and Performance

Other Pharmaceuticals

Company Profile